ALDX Stock Analysis: Aldeyra The | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 138m USD | 12M Return: -48.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.02M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality
Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company focused on immune-mediated and metabolic diseases. The biotechnology sector is characterized by high research and development costs and long product development cycles.
Their primary drug candidate, reproxalap, is a RASP modulator in Phase III trials for dry eye disease and allergic conjunctivitis. Another candidate, ADX-2191, targets retinitis pigmentosa. The company also has ADX-629, an oral RASP modulator, in Phase 2 trials for multiple indications including COVID-19 and asthma. The business model for biotechnology companies often involves extensive clinical trials and regulatory approvals.
Aldeyra is also advancing a preclinical RASP platform with several early-stage compounds for inflammatory and metabolic conditions. Further research on ValueRay can provide more in-depth analysis of ALDXs pipeline and market position.
- Reproxalap FDA approval for dry eye disease drives revenue
- Clinical trial failures for lead candidates impact valuation
- Competition from established ophthalmology treatments limits market share
- Pipeline expansion into new indications diversifies revenue streams
- Regulatory delays for ADX-2191 extend development timelines
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 9.96 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.39 > 3% & CFO -26.0m > Net Income -27.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.3m) vs 12m ago 0.72% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.26%; Δ -0.26% > 0%) |
| Interest Coverage Ratio: -13.48 > 6 (EBIT TTM -25.5m / Interest Expense TTM 1.89m) |
| A: 0.63 (Total Current Assets 66.3m - Total Current Liabilities 24.3m) / Total Assets 66.5m |
| B: -7.33 (Retained Earnings -487.4m / Total Assets 66.5m) |
| C: -0.32 (EBIT TTM -25.5m / Avg Total Assets 79.8m) |
| D: 1.73 (Book Value of Equity 42.2m / Total Liabilities 24.3m) |
| Altman-Z'' = -20.09 = D |
As of July 08, 2026, the stock is trading at USD 2.23 with a total of 2,134,903 shares traded. Over the past week, the price has changed by +8.78%, over one month by +28.16%, over three months by +46.71% and over the past year by -48.74%.
Current recommended Stop Loss: 1.70 (which is 23.8% or 2.9 ATR below the current price).
Aldeyra The has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy ALDX.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.6 | 240.8% |
P/B = 3.2481
Revenue TTM = 0.0 USD
EBIT TTM = -25.5m USD
EBITDA TTM = -25.2m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 15.5m USD (from shortTermDebt, last quarter)
Debt = 15.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 213k
Net Debt = -49.3m USD (calculated: Debt 15.7m - CCE 65.0m)
Enterprise Value = 88.3m USD (137.5m + Debt 15.7m - CCE 65.0m)
Interest Coverage Ratio = -13.48 (Ebit TTM -25.5m / Interest Expense TTM 1.89m)
EV/FCF = -3.40x (Enterprise Value 88.3m / FCF TTM -26.0m)
FCF Yield = -29.44% (FCF TTM -26.0m / Enterprise Value 88.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 258k) / Revenue TTM)
Tobins Q-Ratio = 1.33 (Enterprise Value 88.3m / Total Assets 66.5m)
Interest Expense / Debt = 12.02% (Interest Expense 1.89m / Debt 15.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -20.1m (EBIT -25.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.72 (Total Current Assets 66.3m / Total Current Liabilities 24.3m)
Debt / Equity = 0.37 (Debt 15.7m / totalStockholderEquity, last quarter 42.2m)
Debt / EBITDA = 1.95 (negative EBITDA) (Net Debt -49.3m / EBITDA -25.2m)
Debt / FCF = 1.90 (negative FCF - burning cash) (Net Debt -49.3m / FCF TTM -26.0m)
Total Stockholder Equity = 47.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.28% (Net Income -27.4m / Total Assets 66.5m)
RoE = -57.34% (Net Income TTM -27.4m / Total Stockholder Equity 47.7m)
RoCE = -53.38% (EBIT -25.5m / Capital Employed (Equity 47.7m + L.T.Debt 0.0))
RoIC = -34.90% (negative operating profit) (NOPAT -20.1m / Invested Capital 57.7m)
WACC = 14.52% (E(137.5m)/V(153.3m) * Re(15.09%) + D(15.7m)/V(153.3m) * Rd(12.02%) * (1-Tc(0.21)))
Discount Rate = 15.09% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 94.39 | Cagr: 0.84%
[DCF] Fair Price = unknown (Cash Flow -26.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.85 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=+31.57% | Revisions=+50% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.08 | Chg30d=+25.75% | Revisions=+17% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.33 | Chg30d=+18.99% | Revisions=+50% | GrowthEPS=+41.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.18 | Chg30d=+30.10% | Revisions=+50% | GrowthEPS=+44.9% | GrowthRev=+1085.0%
[Analyst] Revisions Ratio: +67% (up=11, down=1)